Vol. 6 (06) pp. 507-509 DOI: 10.21474/IJAR01/7238

SAFETY AND EFFICACY OF THALIDOMIDE IN PATIENTS WITH POEMS SYNDROME: A CASE REPORT.

, , and
  • D?partement of internal medicine, university hospitals Mohamed VI Marrakesh, Morrocco.
11 Downloads 84 Views
Crossref

Download Full Paper (PDF)

Abstract

Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, and Skin changes (POEMS) syndrome is a typical form of monoclonal gammapathy of clinical significance (MGCS). The acronym MGCS was coined by Jean-Paul Fermand and colleagues(1)to generalise the notion of monoclonal gammapathy of renal significance, in which the toxicity of a monoclonal immunoglobulin produced by a B-cell clone is directed against various renal structures(2). The first case of POEMS syndrome successfully treated with thalidomide was reported in 2004(3). The authors then reported that thalidomide reduced serum VEGF concentrations and increased nerve conduction velocity in nine patients who were not suitable for autotransplantation because of advanced age or severe illness. We aimed to assess the efficacy and safety of thalidomide for the treatment of POEMS syndrome about one case.

Keywords

Article Analytics

References

  1. Nelson Leung,1,2 Frank Bridoux, on behalf of the International Kidney and Monoclonal Gammopathy Research Group online October 9, 2012 doi:10.1182/blood-2012-07-445304 originally published .
  2. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520?30.
  3. Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004; 76: 66?68.
  4. Ofran Y, Yishay O, Elinav E, Eran E. POEMS syndrome: failure of newly suggested diagnostic criteria to anticipate the development of the syndrome.?Am J Hematol. 2005 Aug. 79(4):316-8.
  5. Morizane R, Sasamura H, Minakuchi H, Takae Y, Kikuchi H, Yoshiya N, et al. A case of atypical POEMS syndrome without polyneuropathy.?Eur J Haematol. 2008 May. 80(5):452-5.
  6. Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.?Blood. 2011 Mar 10.
  7. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.?Eur J Haematol. 2008 May. 80(5):397-406.
  8. Misawa S, Sato Y, Katayama K, For the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2016; published online Aug 2. S1474-4422(16).
  9. Kuwabara S, Misawa S, Kanai K, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J NeurolNeurosurg Psychiatry 2008; 79: 1255?57.
  10. Inoue D, Kato A, Tabata S, Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide. Intern Med 2010; 49: 461?66.
  11. Royer B, Merlusca L, Abraham J, Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013; 88: 207?12.
  12. Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I. Long term melphalan-prednisolone chemotherapy for POEMS syndrome. J NeurolNeurosurg Psychiatry 1997; 63: 385?87.
  13. Li J, Zhang W, Jiao L, Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011; 117: 6445?49.
  14. Tang X, Shi X, Sun A, Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009; 83: 609?10.
  15. Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003; 79: 127?32.

How to Cite This Article

Charifa Bassit, Jaouad Yousfi, Mouna Zahlane and Lamiaa Essaadouni. (2018); SAFETY AND EFFICACY OF THALIDOMIDE IN PATIENTS WITH POEMS SYNDROME: A CASE REPORT., Int. J. of Adv. Res., 6 (06), 507-509, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/7238

Corresponding Author

BASSIT

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.